October 04, 2011 08:08 ET

High Demand for Monoclonal Antibodies Will Drive the Therapeutic Proteins Market

ROCKVILLE, MD--(Marketwire - Oct 4, 2011) - has announced the addition of the new report "Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market," to their collection of Antibody Technologies market reports. For more information, visit

The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies considered to be the highest revenue generating market in 2010. This will also be the leading market in the coming years. The global therapeutic proteins market was worth $93 billion in 2010 and is forecast to grow to $141.5 billion by 2017, which represents a growth rate of 6.2% between 2010 and 2017. With the advancements in the biogenerics and gene therapy markets, the therapeutic proteins market is expected to show a moderate growth rate in the coming years. On the other hand, the introduction of new oral therapeutic proteins will increase the patient pool due to better drug compliance. Even though the competition from gene therapy and the biogenerics market will influence the market, the market is still very attractive for the pharmaceutical companies.

The therapeutic proteins market has a moderate pipeline base, supporting growth in the market and thereby attracting the pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Amgen, Roche and Johnson & Johnson have active therapeutic proteins pipelines. One of the major activities in the market at present is the development of generic versions of off-patent drugs. The entry of these generic versions will boost the therapeutic proteins market and thereby bring about further growth in the therapeutic proteins market in the coming years. The rapid entry of new players is set to intensify competition in this market.

The global therapeutic proteins market is dominated by three major pharmaceutical companies, which account for a significant percentage of the market. The top company is Roche, followed by Amgen and Novo Nordisk. Although three top companies dominate the market, there are also a number of small pharmaceutical companies in the market, making it a strong market in terms of competition. However, the development of blockbuster drugs has made these three companies the dominant players in the market. Roche markets Rituxan, Epogin, Herceptin, Pegasys, and Nutropin have total revenues of $22.4 billion; Amgen markets Aranesp, Neupogen, and Neulasta have total revenues of $19.7 billion; Novo Nordisk, through its drugs Novolin and Novolog, has total revenues of $8.6 billion in the therapeutic proteins market.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact